GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Corcept Therapeutics CORT · USD

Health Care · US listing · 🇺🇸 United States

Compare

75.03

+3.11%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$761.4m

FY2016FY2025

Net income

$99.7m

FY2016FY2025

Free cash flow

$141.8m

FY2016FY2025

Shareholders' equity

$647.8m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$761.4m$675.0m$482.4m$401.9m$366.0m$353.9m$306.5m$251.2m$159.2m$81.3m
Gross profit$748.4m$664.2m$475.9m$396.5m$360.7m$348.3m$301.0m$246.0m$155.6m$79.3m
Research and development$254.9m$246.9m$184.4m$131.0m$113.9m$114.8m$89.0m$75.2m$40.4m$23.8m
Operating income$44.8m$137.0m$107.3m$112.6m$124.5m$128.2m$111.6m$89.5m$52.9m$10.2m
Net income$99.7m$139.7m$106.1m$101.4m$112.5m$106.0m$94.2m$75.4m$129.1m$8.1m
Diluted earnings per share0.831.180.960.870.920.830.770.601.010.07

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$836.7m$840.6m$621.5m$583.4m$423.8m$571.7m$412.3m$311.7m$220.5m$68.8m
Cash and short-term investments$372.2m$383.3m$368.2m$431.7m$223.5m$476.9m$276.0m$206.8m$104.0m$51.5m
Total liabilities$188.8m$161.0m$114.8m$81.6m$48.0m$48.4m$41.1m$35.8m$29.6m$27.4m
Debt—————————$14.7m
Shareholders' equity$647.8m$679.6m$506.7m$501.8m$375.8m$523.3m$371.2m$275.9m$191.0m$41.4m
Shares outstanding120m118m111m116m122m127m123m125m127m113m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$142.0m$198.1m$127.0m$120.3m$167.9m$152.0m$136.1m$115.7m$60.9m$18.4m
Capital spending−$211,000−$2.2m−$139,000−$413,000−$469,000−$1.2m−$1.1m−$298,000−$419,000−$194,000
Free cash flow$141.8m$195.9m$126.9m$119.9m$167.4m$150.7m$135.0m$115.4m$60.5m$18.2m
Dividends paid———−$23.9m−$14.2m−$21.5m−$7.0m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$256.1m$164.9m$202.1m$207.6m$194.4m$157.2m$181.9m$182.5m
Gross profit$252.1m$162.0m$199.6m$203.0m$191.0m$154.8m$178.9m$179.7m
Operating income$41.3m−$49.6m$4.5m$10.2m$26.7m$3.4m$25.3m$46.6m
Net income$42.1m−$31.2m$24.3m$19.7m$35.1m$20.5m$30.4m$46.7m
Diluted earnings per share0.36-0.260.200.160.290.170.260.39
Cash from operations$33.0m−$16.0m$38.0m$54.0m$43.0m$5.0m$59.0m$73.0m
Capital spending−$2.0m——————−$1.0m
Free cash flow$31.0m——————$72.0m
Total assets$888.7m$814.9m$836.7m$823.6m$801.7m$846.5m$840.6m$784.3m
Cash and short-term investments$308.2m$338.2m$372.2m$421.7m$342.2m$322.8m$383.3m$380.3m
Debt$1.9m$1.6m$1.1m$1.1m$1.0m$984,000$829,000$432,000
Shareholders' equity$705.8m$638.0m$647.8m$631.9m$635.8m$683.3m$679.6m$638.8m

Financial ratios

Data as of 21 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross margin98.3%98.4%98.7%98.7%98.6%98.4%———
Operating margin8.7%23.9%25.8%28.0%34.0%36.2%———
Net margin13.1%20.7%22.0%25.2%30.7%30.0%———
Return on equity15.4%20.6%20.9%20.2%29.9%20.3%———
Return on assets11.9%16.6%17.1%17.4%26.6%18.5%———
Free cash flow yield1.0%1.5%1.0%0.9%1.2%1.0%———
Revenue growth12.8%39.9%20.0%9.8%3.4%15.5%———
Earnings growth-28.7%31.6%4.7%-9.9%6.1%12.6%———
Current ratio2.92x3.35x4.39x6.89x5.60x49.67x———
Debt to equity0.00x0.00x0.00x0.00x0.00x0.00x———
Equity ratio77.4%80.9%81.5%86.0%88.7%91.5%———
Interest coverage———31.67x34.62x22.74x22.01x33.68x1078.67x
R&D as a share of sales33.5%36.6%38.2%32.6%31.1%32.4%———
Buybacks as a share of market value-1.2%-6.8%4.7%5.0%3.9%-3.9%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue23.7%16.6%31.2%
Operating income-26.5%-19.0%—
Net income-0.6%-1.2%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin98.3%98.5%98.5%98.3%
Operating margin12.7%17.3%21.5%23.5%
Net margin16.7%19.3%21.9%24.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings41.921.216.811.610.715.67.811.08.849.9
Price to sales5.54.43.72.93.34.72.43.37.25.0

Market value over time

30 Nov 2016 to 20 Oct 2026, in USD

$973.2m$13.79bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return56%68%54%-2%-22%111%-3%-18%90%79%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.